The Ingelsson Lab
Human genetics and other population-based methods in combination with molecular biology in cell and in vivo models to discover novel biology and drug targets related to insulin resistance and cardiovascular disease
The primary focus of our laboratory is the link between metabolic disturbances, such as obesity and insulin resistance, and the development of subclinical and clinical cardiovascular disease. Our research is translational and interdisciplinary, combining population studies - specifically genomics and other -omics studies - with molecular biology using in vivo and in vitro models to reach new insights into the pathophysiology of insulin resistance and cardiometabolic diseases, identification of new biomarkers for improved risk prediction, and discovery of novel targets for drug development.
Our team has led many large efforts identifying new loci associated with cardiovascular and metabolic traits, and we have extensive experience from research on biomarkers and -omics methods, including development and use of prediction metrics and Mendelian randomization. We are leading –omics efforts in several cohort studies, including ULSAM, PIVUS, TwinGene and EpiHealth, and use the UK Biobank routinely in our projects.
Since 2013, we have refocused much of our research efforts towards characterization of genes discovered in genome-wide association studies using a combination of in-depth studies in human (including various -omics methods), in vitro studies (primarily adipocytes, hepatocytes and skeletal myocytes) and in vivo models (mice and zebrafish).